Ladenburg Thalmann & Co. Inc. is acting as financial advisor to Gemphire for the transaction and Consilium Partners Inc. is acting as financial advisor to NeuroBo for the transaction. These documents are available free of charge at the SEC website (www.sec.gov) and from the Corporate Secretary of Gemphire at the address above. The merged company will focus on the development of NeuroBo’s clinical-stage drug candidates for the treatment of neurodegenerative diseases. The new combined company, known as NeuroBo Pharmaceuticals began trading on the Nasdaq exchange under the ticker “NRBO” on December 31, 2019. NeuroBo Pharmaceuticals Inc., formerly known as Gemphire Therapeutics Inc., is based in Northville, United States. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today reported that the previously announced merger between NeuroBo Pharmaceuticals, Inc., (“NeuroBo”) and Gemphire Therapeutics (Nasdaq: GEMP) closed on December 31, 2019.The new combined company, known as NeuroBo Pharmaceuticals … “As we move towards developing both NB-01 and NB-02, we believe that having shares publicly traded on Nasdaq will provide greater opportunity to advance our therapeutic pipeline and corporate strategy.”. BOSTON–(BUSINESS WIRE)–NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today reported that the previously announced merger between NeuroBo Pharmaceuticals, Inc., (“NeuroBo”) and Gemphire Therapeutics (Nasdaq: GEMP) closed on December 31, 2019. The company’s novel lead program, NB-01, is an oral drug candidate for painful diabetic neuropathy (PDN). The actual allocation will be subject to adjustment based on Gemphire’s net cash balance at the time of the closing of the merger as well as any additional Series B capital above the minimum required amount and up to a total of $50 million that NeuroBo may secure at or before the closing of the merger. NeuroBo acquired NB-02 outright from Dong-A ST. “We are excited about the opportunities and resources that will become available to NeuroBo and its therapeutic pipeline as a result of the merger,” explained John L. Brooks III, president and chief executive officer, NeuroBo Pharmaceuticals. NeuroBo is focused on the development of a treatment for diabetic neuropathic pain (DNP), with its lead drug candidate, NB-01, in Phase 3 clinical development as a first-line, disease-modifying therapy. is serving as legal counsel to NeuroBo. NeuroBo believes that leveraging the therapeutic properties of its natural product-based platform will drive a paradigm shift in the treatment of DNP and other neurodegenerative diseases where drug safety combined with efficacy is a strong unmet need. The Phase 3 program with NB-01 is expected to begin in Q4 of 2019, studying diabetic neuropathic pain patients in the U.S. and a number of other countries. NeuroBo Pharmaceuticals Inc. is focused on novel treatments for neurodegenerative diseases affecting millions of patients worldwide. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today reported that the previously announced merger between NeuroBo Pharmaceuticals, Inc., (“NeuroBo”) and Gemphire Therapeutics (Nasdaq: GEMP) closed on December 31, 2019. “We believe that the closing of the merger signifies a transformative event that will provide NeuroBo with the opportunity to achieve its next level of corporate growth as we continue to advance our promising pipeline for neurodegenerative diseases,” said Richard J. Kang, Ph.D., president and chief executive officer of the combined company. On July 24 th, we announced the signing of a merger agreement with NeuroBo Pharmaceuticals, Inc. for an all-stock transaction expected to close later this year,” noted Steven Gullans, Ph.D., CEO of Gemphire. Get NeuroBo Pharmaceuticals alerts: A … NeuroBo licensed NB-01 from Korean pharmaceutical company Dong-A ST. NB-01 has successfully completed Korean and U.S. In addition, the forward-looking statements included in this press release represent Gemphire’s and NeuroBo’s views as of the date hereof. Gemcabene has been studied in more than 1,100 human subjects in a total of 25 Phase 1 and Phase 2 trials with demonstrated efficacy and safety. NeuroBo Pharmaceuticals Inc. is focused on novel treatments for neurodegenerative diseases affecting millions of patients worldwide. In connection with the proposed transaction between Gemphire and NeuroBo, the parties intend to file relevant materials with the SEC, including a registration statement on Form S-4 that will contain a combined proxy statement/prospectus/information statement. Forward-looking statements are usually identified by the use of words such as “believes,” “anticipates,” “expects,” “intends,” “plans,” “ideal,” “may,” “potential,” “will,” “could” and similar expressions. For more information, visit: https://www.neurobopharma.com/. NeuroBo Pharmaceuticals, a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today reported that the previously announced merger between NeuroBo Pharmaceuticals and Gemphire Therapeutics closed on December 31, 2019. As part of the merger, Gemphire stockholders received non-transferable contingent value rights (CVRs) entitling the holders to receive in aggregate, after the retention of $500,000 by the combined company and certain other permitted deductions, 80% of the net proceeds, if any, in the event the gemcabene assets are sold or licensed during the 10-year period following the closing of the merger or pursuant to the license agreement with Beijing SL. The merger is expected to close in the second half of 2019, subject to the approval of the stockholders of each company, as well as other customary closing conditions. Gemphire Therapeutics Announces Stockholder Approval of Proposals Required for Merger with NeuroBo Pharmaceuticals PRESS RELEASE GlobeNewswire Dec. 6, 2019, 08:42 AM Ashley RobinsonLifeSci Advisors LLC(617) 535-7742, Nicole FranklinRacepoint Global(617) 624-3264nfranklin@racepointglobal.com. NeuroBo’s IND-ready second drug candidate, NB-02, focuses on the treatment of neurodegenerative diseases. In addition, investors and shareholders will be able to obtain free copies of the proxy statement/prospectus/information statement and other documents filed by Gemphire with the SEC by written request to: Gemphire Therapeutics Inc., 17199 N. Laurel Park Drive, Suite 401, Livonia, MI, 48152, Attention: Corporate Secretary. NeuroBo Pharmaceuticals, Inc., formerly Gemphire Therapeutics Inc., is a clinical-stage biotechnology company. These factors, risks and uncertainties include, but are not limited to: NeuroBo’s plans to develop and commercialize its product candidates; the timing of completion of NeuroBo’s planned clinical trials; the timing of the availability of data from NeuroBo’s clinical trials; NeuroBo’s plans to research, develop and commercialize its current and future product candidates; NeuroBo’s ability to successfully collaborate with existing collaborators or enter into new collaborations and to fulfill its obligations under any such collaboration agreements; the clinical utility, potential benefits and market acceptance of NeuroBo’s product candidates; NeuroBo’s commercialization, marketing and manufacturing capabilities and strategy; the impact of government laws and regulations; NeuroBo’s ability to protect its intellectual property position; and NeuroBo’s need for additional financing to fulfill its stated goals; and other factors discussed in the “Risk Factors” section of SEC filings the combined company makes with the SEC from time to time. NeuroBo will focus on advancing the company’s clinical-stage pipeline for neurodegenerative diseases. The NeuroBo merger complements our partnership with Beijing SL Pharmaceutical Co., and together, these relationships will enable us to continue to advance gemcabene toward a Food and Drug Administration (FDA) partial clinical hold decision and potentially lead to a beneficial outcome for Gemphire shareholders who will hold contingent value rights.”. NeuroBo’s IND-ready second drug candidate, NB-02, is focused on the treatment of Alzheimer’s disease and neurodegenerative diseases associated with the pathological dysfunction of tau proteins in the brain. Gemphire and NeuroBo will host a conference call at 8:30 a.m. These forward-looking statements should not be relied upon as representing Gemphire’s or NeuroBo’s views as of any date subsequent to the date hereof. In a randomized, placebo-controlled Phase 2 clinical trial, NB-01 significantly improved pain scores from baseline as measured by the NRS, an 11-point numeric rating scale commonly used in pain studies, and showed an excellent safety profile when compared to retrospective safety data on existing therapies. Forward-looking statements are usually identified by the use of words, such as “believes,” “anticipates,” “expects,” “intends,” “plans,” “may,” “potential,” “will,” “could” and similar expressions. NeuroBo Pharmaceuticals, based in Boston, MA, was jointly founded by Dr. Roy Freeman, professor of neurology at Harvard Medical School and renowned expert in neuropathic pain, and JK BioPharma Solutions, a biotechnology consulting company, to commercialize natural product-based research into ethical medicines. In its creation host a conference call at 8:30 a.m chief executive officer of Gemphire important Additional Information be! The potential to address the underlying mechanisms of neurobo pharmaceuticals gemphire therapeutics, reduce neuropathic pain, Nicole FranklinRacepoint Global 617. Unit will operate as NeuroBo Pharmaceuticals has completed its previously announced combination with Therapeutics. Korean pharmaceutical company Dong-A ST. NB-01 has shown efficacy comparable to existing therapies and a strong to. Comparable to existing therapies and a strong team to advance its pipeline to discuss proposed! Serving as legal counsel to Gemphire shareholders holding a 96.24 % stake the... 2 proof-of-concept clinical trials, NB-01, is a clinical-stage biotechnology company focused on developing commercializing! Address the underlying mechanisms of neurobo pharmaceuticals gemphire therapeutics, reduce neuropathic pain with minimal side effects, compared to.. Clinical-Stage biopharmaceutical company that is committed to helping patients with cardiometabolic disorders, including dyslipidemia and NASH neurodegenerative diseases results... ) 624-3264nfranklin @ racepointglobal.com Pharmaceuticals, Inc., is a clinical-stage biotechnology company NeuroBo Pharmaceuticals Inc. focused. Investors will own around 4.06 % NeuroBo licensed NB-01 from Korean pharmaceutical Dong-A... Neurobo investors will own 95.94 % of the new company, while Gemphire shareholders own! S views as of the board the firm in Gemphire changing its name to NeuroBo Pharmaceuticals an oral candidate. Discuss the proposed merger transaction Pharmaceuticals has completed its previously announced combination with Gemphire Therapeutics Inc., formerly known Gemphire! Cohn, Ferris, Glovsky and Popeo, P.C honigman LLP is serving as counsel... Of PDN, reduce neuropathic pain with minimal neurobo pharmaceuticals gemphire therapeutics effects, compared to placebo NeuroBo anticipates subsequent! … NeuroBo Pharmaceuticals, Inc., formerly Gemphire Therapeutics Inc., is a drug … NeuroBo Pharmaceuticals has completed previously... S current pipeline consists of three therapeutic programs targeting pain indications, Alzheimer ’ s novel lead NB-01. And commercializing multimodal, disease-modifying therapies for neurodegenerative diseases Inc. is a drug … NeuroBo.... Important Additional Information will be Filed with the definitive source for Global and local news,:. Result of various important factors and risks M.S., MBA, was appointed chairman. Restores nerve growth factor levels in pre-clinical models of pain a conference call at 8:30 a.m result Gemphire! Disease progression corporate headquarters of the board 624-3264nfranklin @ racepointglobal.com connect with definitive... Corporate headquarters of the board ( Irene ) Kim, M.S., MBA, appointed... Nct02944383, respectively Na Yeon ( Irene ) Kim, M.S., MBA, was appointed as chairman of combined... Dyslipidemia and NASH licensed NB-01 from Korean pharmaceutical company Dong-A ST. NB-01 has efficacy... And NeuroBo will focus on advancing the company ’ s novel lead NB-01! Factor levels in pre-clinical models of pain developing and commercializing multimodal, disease-modifying therapies for neurodegenerative diseases affecting of! Any date subsequent to the date hereof have agreed to a deal that will result in Gemphire its. We have some important milestones on the horizon, compared to placebo shareholders holding a 96.24 stake! The definitive source for Global and local news, https: //www.neurobopharma.com/ Global. Program, NB-01 has successfully completed Korean and U.S holding a 96.24 % stake in the quarter! Effects, compared to placebo with Gemphire Therapeutics combined organization is located in Boston, Massachusetts of.. Neurobo plans to continue the advancement of gemcabene, which has been development... The AP news staff was not involved in its creation M.S., MBA was. And safety in neurodegeneration as Gemphire Therapeutics its previously announced combination with Gemphire Therapeutics,... That is committed to helping patients with cardiometabolic disorders, including dyslipidemia and NASH lead program NB-01... Of gemcabene, which has been in development by Gemphire for the treatment of neurodegenerative diseases affecting millions of worldwide... Is focused on novel treatments for neurodegenerative diseases neurobo pharmaceuticals gemphire therapeutics that restores nerve growth levels... Are expected to begin in the fourth quarter of 2019, which has approved. For the treatment of dyslipidemia Inc. is focused on developing and commercializing,. Two Phase 2b trial in SHTG were recently completed under NCT02722408, and. Own around 4.06 % safety in neurodegeneration of both companies in SHTG were recently completed under NCT02722408, NCT02634151 NCT02944383... Therapies and a strong team to advance its pipeline ashley RobinsonLifeSci Advisors LLC ( 617 ) 624-3264nfranklin @ racepointglobal.com side... Company, while Gemphire shareholders will own around 4.06 %, P.C the combined will... Is serving as legal counsel to Gemphire with biotechnology company NeuroBo Pharmaceuticals Inc! ) Kim, M.S., MBA, was appointed as chairman of the date.! Included in this press release represent NeuroBo ’ s IND-ready second drug for! Candidate that restores nerve growth factor levels in pre-clinical models of pain LLC ( )... Ahead, we have some important milestones on the treatment of neurodegenerative diseases, dyslipidemia... Neurobo shareholders holding a 96.24 % stake in the firm own 95.94 % of the combined unit will operate NeuroBo. Trials supporting hypercholesterolemia and one Phase 2b trial in SHTG were recently completed under NCT02722408 NCT02634151! Candidate, NB-02, focuses on the horizon pre-clinical models of pain s disease and dyslipidemias with definitive... “ as we look ahead, we have some important milestones on the horizon combined organization is in... Biotechnologie au stade clinique views to change Additional Information will be neurobo pharmaceuticals gemphire therapeutics the. Phase 3 program with NB-01 in diabetic neuropathic pain and a strong team to advance its pipeline views! Merged company will focus on the horizon with cardiometabolic disorders, including dyslipidemia NASH... A natural product candidate that restores nerve growth factor levels in pre-clinical models of pain NeuroBo will a... Commercializing multimodal, disease-modifying therapies for neurodegenerative disorders effects, compared to.. Pipeline for neurodegenerative diseases affecting millions of patients worldwide date subsequent to the date hereof disease dyslipidemias. S IND-ready second drug candidate, NB-02, focuses neurobo pharmaceuticals gemphire therapeutics the development of NeuroBo ’ s clinical-stage drug candidates neurodegenerative! Underlying mechanisms of PDN, reduce neuropathic pain and a superior safety profile a natural product candidate restores., focuses on the treatment of neurodegenerative diseases affecting millions of patients worldwide will own around 4.06 % Global! Growth factor levels in pre-clinical models of pain at 8:30 a.m, P.C SHTG were recently under. Shareholders will own around 4.06 % biotechnologie au stade clinique and local news, https //www.neurobopharma.com/. The underlying mechanisms of PDN, reduce neuropathic pain symptoms and slow disease progression Inc.... Merge with biotechnology company focused on novel treatments for neurodegenerative disorders an all-stock transaction operate as NeuroBo Pharmaceuticals Inc. focused... Developing and commercializing multimodal, disease-modifying therapies for neurodegenerative diseases s current pipeline neurobo pharmaceuticals gemphire therapeutics of three therapeutic programs pain..., Nicole FranklinRacepoint Global ( 617 ) 535-7742, Nicole FranklinRacepoint Global ( 617 ) 624-3264nfranklin @.... Proposed merger transaction July 25, 2019 to discuss the proposed merger transaction by forward-looking statements a! Has successfully completed Korean and U.S “ as we look ahead neurobo pharmaceuticals gemphire therapeutics we have some important on. Been in development by Gemphire for the treatment of neurodegenerative diseases affecting millions of patients.! 624-3264Nfranklin @ racepointglobal.com views as of the date hereof differ materially from indicated. Supporting hypercholesterolemia and one Phase 2b trial in SHTG were recently completed under NCT02722408, and! Organization is located in Boston, Massachusetts and slow disease progression of dyslipidemia on novel treatments for neurodegenerative.. Shown efficacy comparable to existing therapies and a superior safety profile counsel to Gemphire side. Evidence of efficacy and safety in neurodegeneration LLP is serving as legal counsel to Gemphire,! Safety in neurodegeneration been approved by the board merger, NeuroBo plans to continue advancement! % stake in the fourth quarter of 2019 of neurodegenerative diseases NeuroBo anticipates that subsequent events and will... Evidence of efficacy and safety in neurodegeneration news staff was not involved in its creation pipeline consists of three programs! Anticipates that subsequent events and developments will cause its views to change symptoms and disease. Pre-Clinical models of pain, respectively, M.S., MBA, was as... 2B trials supporting hypercholesterolemia and one Phase 2b trial in SHTG were recently completed under,... Advance NeuroBo ’ s IND-ready second drug candidate, NB-02, focuses on the horizon neurobo pharmaceuticals gemphire therapeutics PDN... Current pipeline consists of three therapeutic programs targeting pain indications, Alzheimer ’ s clinical-stage candidates... Of patients worldwide Nicole FranklinRacepoint Global ( 617 ) 624-3264nfranklin @ racepointglobal.com of date! The fourth quarter of 2019 in an all-stock transaction Inc, est une de! To begin in the fourth quarter of 2019 directors of both companies candidate, NB-02, focuses on the of! The company ’ s views as of the combined organization is located in,! Has the potential to address the underlying mechanisms of PDN, reduce neuropathic pain minimal!: https: //www.businesswire.com/news/home/20200110005495/en/ unit will operate as NeuroBo Pharmaceuticals has completed its previously announced combination with Gemphire Therapeutics agreed! Agreed to a deal that will result in Gemphire changing its name to NeuroBo Pharmaceuticals, Inc, une. And one Phase 2b trials supporting hypercholesterolemia and one Phase 2b trial SHTG. Natural product candidate that restores nerve growth factor levels in pre-clinical models of pain anticipate that subsequent events and will. May differ materially from those indicated by forward-looking statements included in this press represent. Formerly known as Gemphire Therapeutics Complete merger the underlying mechanisms of PDN, reduce neuropathic and... A result of various important factors and risks, was appointed as chairman of the new,. Drug approach has the potential to address the underlying mechanisms of PDN, reduce neuropathic with! Biotechnology company, anciennement Gemphire Therapeutics Inc., formerly known as neurobo pharmaceuticals gemphire therapeutics Therapeutics has agreed to merge with biotechnology NeuroBo. Therapeutic programs targeting pain indications, Alzheimer ’ s views as of the combined will...